A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
- Conditions
- Obesity
- Interventions
- Drug: PlaceboDrug: BI 456906
- Registration Number
- NCT04667377
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight.
Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine.
Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 387
- Adult ≥ 18 years and < 75 years of age at screening
- Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
- Obesity or Overweight defined as BMI ≥27 kg/m2 at screening
- A minimum absolute body weight of 70 kg for females and 80 kg for males at screening
- Male or female participants. Women of childbearing potential (WOCBP)1 must be willing and able to use two forms of effective contraception where at least one form is highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
- Patients must have undergone at least one previous unsuccessful nonsurgical weight-loss attempt per investigator's judgement
Exclusion criteria:
- Body weight change of over +/- 5% or more in the past 12 weeks prior to randomization. There must be documentation of weight in the past 12 weeks before randomization.
- Obesity induced by an endocrinologic disorder (i.e. Cushing Syndrome, hypogonadism, growh hormone deficiency. However, well controlled hypothyroidism, polycystic ovarian disease are still allowed)
- A HbA1c ≥ 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus
- Exposure to Glucagon like peptide-1 receptor agonist (GLP-1Ra) based therapies within three months prior to screening
- Any suicidal behaviour in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-Suicide Severity Rating Scale (CSSRS) within 3 months before screening, or during screening period
- History of major depressive disorder within 2 years before randomization
- Major depressive symptoms (defined as a screening Patient Health Questionnaire-9 [PHQ-9] score ≥15) at screening and/or during screening period
- Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders at screening
- Chronic or relevant acute infections (including but not limited to respiratory tract infections, urinary tract infection, bladder infection, enterocolitis, abscess, tuberculosis, meningitis, influenza, Epstein-Barr virus, HIV/AIDS, and hepatitis B or C, and severe acute respiratory syndrome coronavirus type 19 (SARS CoV-2) (as confirmed by Polychain reaction (PCR) test)), within 2 weeks from screening or during screening.
- Further exclusion criteria apply
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo group Placebo - 2.4 mg BI456906 BI 456906 - 3.6 mg BI 456906 BI 456906 - 4.8 mg BI 456906 BI 456906 - 0.6 mg BI 456906 BI 456906 -
- Primary Outcome Measures
Name Time Method Percentage Change in Body Weight From Baseline to Week 46 Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".
- Secondary Outcome Measures
Name Time Method Absolute Change in Waist Circumference From Baseline to Week 46 Baseline, Week 6, 12, 18, 24, 32, 40, and 46. Absolute change in waist circumference from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline waist circumference as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 6, 12, 18, 24, 32, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Weight Loss of ≥ 5% of Baseline Weight at Week 46 At baseline and at Week 46. Weight loss of greater than or equal to 5 percent (≥5%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥5% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Weight Loss of ≥ 10% of Baseline Weight at Week 46 At baseline and at Week 46. Weight loss of greater than or equal to 10 percent (≥10%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥10% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Weight Loss of ≥ 15% of Baseline Weight at Week 46 At baseline and at Week 46. Weight loss of greater than or equal to 15 percent (≥15%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥15% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.
Absolute Change in Systolic Blood Pressure From Baseline to Week 46 Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. Absolute change in systolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline systolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Absolute Change in Body Weight From Baseline to Week 46 Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. Absolute change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Absolute Change in Diastolic Blood Pressure From Baseline to Week 46 Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46. Absolute change in diastolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline diastolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.
Trial Locations
- Locations (43)
Valley Weight Loss Clinic
🇺🇸Fargo, North Dakota, United States
Nepean Hospital
🇦🇺Kingswood, New South Wales, Australia
Lucas Research, Inc.
🇺🇸Morehead City, North Carolina, United States
PMG Research of Wilmington, LLC
🇺🇸Wilmington, North Carolina, United States
EB Flevoresearch
🇳🇱Almere, Netherlands
Ladulaas Kliniska Studier
🇸🇪Borås, Sweden
Recherche GCP Research
🇨🇦Montreal, Quebec, Canada
L-MARC Research Center
🇺🇸Louisville, Kentucky, United States
Franciscus Gasthuis
🇳🇱Rotterdam, Netherlands
Akademiska sjukhuset
🇸🇪Uppsala, Sweden
Bluewater Clinical Research
🇨🇦Sarnia, Ontario, Canada
The Catholic University of Korea, Yeouido St.Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Waterloo Medical Centre
🇬🇧Blackpool, United Kingdom
Salvia Lekston I Madej Sp. J.
🇵🇱Katowice, Poland
Albert SchweitzerZiekenhuis
🇳🇱Zwijndrecht, Netherlands
Forskningsenheten Carlanderska
🇸🇪Göteborg, Sweden
Klinische Forschung Berlin GbR
🇩🇪Berlin, Germany
Metabolic Health Center Pawel Bogdanski
🇵🇱Poznan, Poland
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Eastern Clinical Research Unit
🇦🇺East Ringwood, Victoria, Australia
Universitätsklinikum Carl Gustav Carus Dresden
🇩🇪Dresden, Germany
Optimal Clinical Trials
🇳🇿Auckland, New Zealand
UZ Leuven
🇧🇪Leuven, Belgium
Kyung Hee University Hospital at Gangdong
🇰🇷Seoul, Korea, Republic of
The First Hospital of Jilin University
🇨🇳Changchun, China
Beijing Chao-Yang Hospital
🇨🇳Beijing, China
Beijing Luhe Hospital Capital Medical University
🇨🇳Beijing, China
Wuhan Union Hospital
🇨🇳Wuhan, China
Velocity Clinical Research, Inc.
🇺🇸Cleveland, Ohio, United States
TLM Medical Services, LLC
🇺🇸Columbia, South Carolina, United States
Coastal Carolina Research Center
🇺🇸North Charleston, South Carolina, United States
The Boden Initiative
🇦🇺Camperdown, New South Wales, Australia
Canadian Phase Onward Inc.
🇨🇦Toronto, Ontario, Canada
LMC Clinical Research Inc. (Bayview)
🇨🇦Toronto, Ontario, Canada
Diablo Clinical Research
🇺🇸Walnut Creek, California, United States
Washington Center for Weight Management and Research, Inc.
🇺🇸Arlington, Virginia, United States
Allegiance Research Specialists
🇺🇸Wauwatosa, Wisconsin, United States
Joanne F Liutkus Medicine Professional Corporation
🇨🇦Cambridge, Ontario, Canada
P3 Research
🇳🇿Newtown Wellington NZ, New Zealand
PT & R
🇳🇱Beek, Netherlands
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
Clifton Medical Centre, Rotherham
🇬🇧Rotherham, United Kingdom
Related News
EASD 2024: Survodutide shows promise in overweight, obesity and MASH
- Prev
- 1
- Next